Skip To Main Content

Utdannelse

Sorter etter

Filter

Nullstille
  • Terapiområde
Preventive Cardiology: Key Insights from Professor Michal Vrablik

Preventive Cardiology: Key Insights from Professor Michal Vrablik

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Type 2 Symposium, Oslo 2023

Type 2 Symposium, Oslo 2023

Type 2 symposium, 2024

Type 2 symposium, 2024

Personalized approach in T2D is key for success

Personalized approach in T2D is key for success

The Sanofi webinar ‘Act Now for Impact: Glycemic Control and Beyond’ focuses on recent advancements in treating type 2 diabetes (T2D), emphasizing a personalized approach for better outcomes. Prof. Frank Nobels (Belgium), prof. De Galan (the Netherlands) and Prof Björn Eliasson (Sweden) addressed various aspects of T2D treatment in the present era.

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262

Hot topics in atopic dermatitis: Hear it from the experts

Hot topics in atopic dermatitis: Hear it from the experts

Introduction to hand and foot dermatitis

Introduction to hand and foot dermatitis

Why Don’t We Strike Early, Strike Strong?

Why Don’t We Strike Early, Strike Strong?

Prof. Dr. Halvorsen, Prof. Dr. Sinnaeve & Prof. Dr. Martens

COPD Research Forum

COPD Research Forum

Rhino Rounds International 2024 - Interview

Rhino Rounds International 2024 - Interview

Slowly Expanded Lesions

Slowly Expanded Lesions

A candidate biomarker for smoldering neuroinflammation in MS.